http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-030008-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b273142130d764e4c9ec79fb0e21ea2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C279-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C279-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-0406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-18 |
| filingDate | 1999-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-08-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-030008-A1 |
| titleOfInvention | PHENYL COMPOUND, USE OF SUCH COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT, ISOTOPICALLY MARKED COMPOUND, DIAGNOSTIC AGENT, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH COMPOUND AND COMPOUND FOR ITS EXCLUSIVE USE |
| abstract | A phenyl compound according to formula (1) in which each of myn is independently an integer of 0û3 and one or more of the hydrogens of said alkyl chain may be optionally substituted with any of C1-6 alkyl, C1 alkoxy -6 or hydroxy or one more of the methylene groups may be optionally substituted with a heteroatom such as O, N or S; R1 is selected from hydrogen, a C1-6 alkyl, C2-6 alkenyl, straight or branched C3-8 cycloalkyl, (C4-8 alkylcycloalkyl), where alkyl is C1-2 alkyl and the cycloalkyl is C3-6 cycloalkyl, R2 is selected from any of (i) hydrogen; (ii) a C1-6 alkyl, C2-6 alkenyl C2-6 alkynyl, straight or branched, (iii) [(Ch2) q-aryl]; (iv) [CH2) r-heteroaryl], where the heteroaryl has 5 to 10 atoms and the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y where each Y is as defined below and where, in addition, each of q and r is independently an integer from 0 to 3; (v) C3-10 cycloalkyl, which optionally contains one or more unsaturations and is optionally substituted with one or more heteroaryl (s) where the heteroaryl has 5 to 10 atoms and the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (vi) C6-10 aryl optional and independently substituted with one or more heteroaryl (s) having 5 to 10 atoms and where the heteroatom (s) are selected from any of S, N and O; and where the heteroaryl may be optional and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (vii) heteroaryl of 5 to 10 atoms and wherein the heteroatom selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y where each Y is as defined below: or R1 and R2 may optionally form a heterocyclic ring that may be optionally saturated or unsaturated; R3 is selected from any of (i) hydrogen; (ii) a C1-6 alkyl, C2-6 alkenyl or straight or branched C2-6 alkynyl, (iii) C6-10 arylalkyl where the aryl may be optionally substituted with one or more heteroaryl (s) of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O; and where the aryl and the heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below (iv) heteroaryl (C5-10 alkyl), where the heteroaryl has 5 to 10 atoms and where the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below. (v) C3-10 cycloalkyl which optionally contains one or more unsaturations and is optionally substituted with one or more heteroaryl (s) of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (vi) [C3-6- cycloalkyl (CH2) q], where q is an integer from 1 to 3; R4 is selected from (i) hydrogen; (ii) a C1-6 alkyl, C2-6 alkenyl or straight or branched C2-6 alkynyl, (iii) C6-10 aralkyl where the aryl may be optionally substituted with one or more heteroaryl (s) of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (iv) heteroaryl (C5-10 alkyl), where the heteroaryl has 5 to 10 atoms and where the heteroatom is selected from any of S, N and O and where the aryl and heteroaryl can be optionally and independently substituted by 1 or 2 Y substituents, where each Y is as defined below; (v) C3-10 cycloalkyl which optionally contains one or more unsaturations and is optionally substituted with one or more heteroaryl (s) of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O, and where the aryl and the heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (vi) C6-10 aryl optional and independently substituted with one or more heteroaryl (s) having 5 to 10 atoms and where the heteroatom (s) are selected from any of S, N and O; and where the heteroaryl may be optional and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (vii) heteroaryl of 5 to 10 atoms and wherein the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted by 1 or 2 substituents Y, where each Y is as defined below; R5 is selected from (i) hydrogen; (ii) a C1-6 alkyl C2-6 alkenyl, C2-6 alkenyl or straight or branched C2-6 alkynyl, (iii) C6-10 arylalkyl, where the aryl may be optionally substituted with one or more heteroaryl (s) of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (iv) heteroaryl (C5-10 alkyl), where the heteroaryl has 5 to 10 atoms and where the heteroatom is selected from any of S, N and O and where the aryl and heteroaryl can be optionally and independently substituted with 1 or 2 Y substituents, where each Y is as defined below. (v) C3-10 cycloalkyl, which optionally contains one or more unsaturations and is optionally substituted with one or more heteroaryl (s) of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (vi) C5-10 aryl, optionally and independently substituted with one or more heteroaryl (s) having 5 to 10 atoms and where the heteroatom (s) are selected from any of S, N and O; and where the heteroaryl may be optional and independently substituted with 1 or 2 substituents Y where each Y is as defined below; (vii) heteroaryl of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O and where the aryl and heteroaryl can be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined later; (viii) structures (2) or (3) where each of R7, R8, R9, R10 and R11 is independently selected from (a) hydrogen; (b) a C1-6 alkyl C2-6 alkenyl or straight or branched C2-6 alkynyl, (c) C6-10 arylalkyl, where the aryl may be optionally substituted with one or more heteroaryl (s) of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (d) heteroaryl (C5-10 alkyl), where the heteroaryl has 5 to 10 atoms and where the heteroatom is selected from any of S, N and O and where the aryl and heteroaryl can be optionally and independently substituted with 1 or 2 Y substituents, where each Y is defined below (e) C3-10 cycloalkyl, which optionally contains one or more unsaturations and is optionally substituted with one or more heteroaryl (s) of 5 to 10 atoms and where the heteroatom is selected from any of S, N and O; and where aryl and heteroaryl may be optionally and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (f) C6-10 aryl optional and independently substituted with one or more heteroaryl (s) having 5 to 10 atoms and where the heteroatom (s) are selected from any of S, N and O and where the heteroaryl may be optional and independently substituted with 1 or 2 substituents Y, where each Y is as defined below; (ix) the structure (4) or R4 and R5 may optionally form a heterocyclic ring that may be optionally saturated or unsaturated. Each Y is independently selected from hydrogen, CH3; - (CH2) p1CF3 halogen, alkoxy, C1-3; hydroxy; -NO2; -OCF3; -CONRaRb, -COORa, -CORa, - (CH2) p2NraRbû (CH2) p3CH3, (CH2) p4SORaRb, - (CH2) p5SO2Ra, (C4-8 alkyl-cycloalkyl) where alkyl is C1-2 alkyl and cycloalkyl is C3 cycloalkyl -6, where 1 or 2 heteroaryls have 5 to 10 atoms and the heteroatom is selected from S, N and O, as well as oxides such as N-oxides or sulfoxides and where Ra and Rb is independently selected from hydrogen, an alkyl C1-6, C1-6 alkenyl or branched or straight C3-8 cycloalkyl, and where each of p1, p2, p3, p4, p5, and p6 is independently 0.1 or 2, as well as pharmaceutically acceptable salts of the compounds of the formula 1 and also the isomers, hydrates, isoforms and prodrugs thereof; its use for the manufacture of a medicine, diagnostic agent, pharmaceutical composition containing it, process for its preparation, intermediary compounds for its exclusive use in the preparation of the compounds of formula 1 and treatment methods. These compounds are useful in therapy, especially in the treatment of various painful disorders such as chronic pain, acute pain, pain caused by cancer, pain caused |
| priorityDate | 1998-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.